mRNA up-regulation of heregulin was observed in clinical breast cancer specimens during trastuzumab-based treatment, but heregulin overexpression had a limited effect on sensitivity to T-DM1 in vitro and in vivo. Here, NRG1 is linked to breast carcinoma.